GlassScriptPhysician profile
Sheel J Patel
NPI 1942566567
$5,221.37
in general payments reported to CMS, 2019-2025
41 companies · $18.03 in 2025
The $18.03 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,748 · 2020: $2,305 · 2021: $26.63 · 2023: $90.67 · 2024: $32.65 · 2025: $18.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $141.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $656.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $448.34 | 2019-2020 | |
| Amgen INC. | $407.58 | 2019-2020 | |
| Astellas Pharma US INC | $354.33 | 2019-2020 | |
| Daiichi Sankyo INC. | $329.77 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $317.82 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $313.67 | 2019-2020 | |
| Janssen Biotech, INC. | $306.51 | 2019-2020 | |
| Lilly USA, LLC | $297.15 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $163.48 | 2020 | |
| Eisai INC. | $157.61 | 2019-2020 | |
| Pfizer INC. | $135.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.18 | 2019-2020 | |
| Seagen INC. | $99.34 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $90.67 | 2023 | Imbruvica, Epkinly |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheel Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.